ers Repeated Setbacks. The New York Times (5/20, Pietsch, 20.6M) examines the COVAX vaccination campaign, and the recent setbacks involving India's Serum Institute and the US' Emergent BioSolutions, which are both behind schedule on the production of their respective vaccines. Serum "has diverted all its manuf